
Reimbursement
Latest News
Latest Videos

CME Content
More News

Expert: ‘Huge Opportunity for Pharmacy Reimbursement’ in Diabetes Self-Management Education Services
Through gamification and food-focused activities, pharmacists can incentivize patient engagement in these services, even if offered outside the pharmacy.

Carlie Traylor, PharmD, director of Strategic Initiatives and Student Affairs at NCPA discussed the growing roles of pharmacists and pharmacy technicians and how COVID-19 has changed the landscape of services offered in community pharmacies.

Kyle McCormick, PharmD, owner of Blueberry Pharmacy, discusses the differences between a traditional pharmacy model and a cost-plus pharmacy model.

Bri Morris, PharmD, senior director of Education and the Long-Term Care Division at the National Community Pharmacists Association, discusses the importance of teamwork in the pharmacy.

The value proposition for point-of-care testing in the pharmacy is extensive, as pharmacies can provide a convenient, accessible, and cost-saving alternative for patients.

Certain states are proposing that out-of-state telemedicine care should be more accessible, which researchers believe is a trend that will continue.

Patients who had previously hit their out-of-pocket maximums could see a significant change.

An overview of the legal and business tools available to community, specialty, hospital, and health-system pharmacies in seeking to maintain payer network access and combat abusive practices.

Vertical and horizontal consolidation has had a significant impact on retail, specialty, and health-system pharmacies.

Although innovation in the pharmacy space is continuing nearly 3 years into the COVID-19 pandemic, provider status and reimbursement are both necessary to continue this innovation in the future.

Although pharmacies have repeatedly proven their value and continue to be essential to providing equitable health care, Jason Ausili, PharmD, said commensurate reimbursement is necessary to move forward.

Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.

We need to be able to build on that momentum, and at the same time, we need sustainable reimbursement models.

There's a lot of complexity in the agreements, so pharmacies like Health Mart Atlas provide reporting and resources.

Pharmacies need to kind of move beyond those models that are more punitive and look for true pharmacy-based measures and the ability to pay for performance and outcomes for patients.

PSAO supports community pharmacies through patient access by unlocking the right payer agreements.

It's really important that we capitalize on this time and the impact that pharmacists had to make some of this reform permanent.

Even before the pandemic, pharmacists were playing a really important role in public health, being one of the most accessible health care providers.

David Pope, PharmD, CDE, the EVP of Innovation and Industry Relations at OmniSYS, discusses the FDA’s announcement updating pharmacists’ prescriptive authority for the COVID-19 antiviral Paxlovid.

Neil Lund, senior advisor, Avelere Health and Ryan Urgo, managing director, Health Policy, Avelere Health, discuss the impact of President Biden’s health care agenda on the pharmacy field.

Jayne Hornung, chief clinical officer – pharmacy, Managed Markets Insight & Technology, discusses her presentation on potential causes of the slow uptake in digital therapeutics among payers.

Jayson Slotnik, JD, MPH, partner at Health Policy Strategies, discusses his hopes for the future of value-based contracting and the ideal model for pharmacy’s involvement.

Melissa Somma McGivney, PharmD, FCCP, FAPhA, professor and associate dean for community partnerships at the University of Pittsburgh School of Pharmacy, gives a brief overview of the best practices when it comes to billing in a pharmacy.

Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

Is big pharma overlooking the Goldilocks solutions right under our nose?